Cargando…
Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652527/ http://dx.doi.org/10.1186/2051-1426-3-S2-P402 |
| _version_ | 1782401773696188416 |
|---|---|
| author | Schaer, David Li, Yanxia Castaneda, Stephen Inigo, Ivan Surguladze, David Xu, Xiaohong Nugent, Desiree Murphy, Mary Hall, Gerald Benhadji, Karim Guba, Susan Li, Yiwen Kalos, Michael Driscoll, Kyla |
| author_facet | Schaer, David Li, Yanxia Castaneda, Stephen Inigo, Ivan Surguladze, David Xu, Xiaohong Nugent, Desiree Murphy, Mary Hall, Gerald Benhadji, Karim Guba, Susan Li, Yiwen Kalos, Michael Driscoll, Kyla |
| author_sort | Schaer, David |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4652527 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46525272015-11-25 Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition Schaer, David Li, Yanxia Castaneda, Stephen Inigo, Ivan Surguladze, David Xu, Xiaohong Nugent, Desiree Murphy, Mary Hall, Gerald Benhadji, Karim Guba, Susan Li, Yiwen Kalos, Michael Driscoll, Kyla J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4652527/ http://dx.doi.org/10.1186/2051-1426-3-S2-P402 Text en Copyright © 2015 Schaer et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Schaer, David Li, Yanxia Castaneda, Stephen Inigo, Ivan Surguladze, David Xu, Xiaohong Nugent, Desiree Murphy, Mary Hall, Gerald Benhadji, Karim Guba, Susan Li, Yiwen Kalos, Michael Driscoll, Kyla Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition |
| title | Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition |
| title_full | Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition |
| title_fullStr | Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition |
| title_full_unstemmed | Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition |
| title_short | Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition |
| title_sort | targeting the tgfβ pathway with galunisertib, a tgfβri smi, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652527/ http://dx.doi.org/10.1186/2051-1426-3-S2-P402 |
| work_keys_str_mv | AT schaerdavid targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT liyanxia targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT castanedastephen targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT inigoivan targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT surguladzedavid targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT xuxiaohong targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT nugentdesiree targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT murphymary targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT hallgerald targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT benhadjikarim targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT gubasusan targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT liyiwen targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT kalosmichael targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition AT driscollkyla targetingthetgfbpathwaywithgalunisertibatgfbrismipromotesantitumorimmunityleadingtodurablecompleteresponsesasmonotherapyandincombinationwithcheckpointinhibition |